Abstract Library

#4592 Uncovering cell-state heterogeneity in large-cell panNEC indicates potentially targetable aberrant brain type neuronal de-differentiation

Introduction: Classification and treatment of high-grade pancreatic neuroendocrine carcinoma (panNEC), particularly those with large-cell morphology, present significant clinical challenges due to considerable inter- and intra-patient tumour heterogeneity.

Conference:

Presenting Author: Debnath O

Authors: Debnath O, Berger H, Detjen K, Kirchner P, Marinoni I,

Keywords: pancreatic neuroendocrine carcinoma, single cell, personalised medicine,

#4041 Mesenteric fibrosis in small intestinal neuroendocrine tumors (SI-NETs): Pathogenesis and therapeutic targets

Introduction: Mesenteric fibrosis (MF) affects up to 50% of small intestine neuroendocrine tumor (SI-NET) patients, causing significant morbidity and mortality. MF pathophysiology is poorly understood, limiting treatment development and biomarker identification.

Conference:

Presenting Author:

Authors: Castanho Martins M, Hodgetts H, Lemos Dias M, Luong T, Hall A,

Keywords: fibrosis, small intestine, 3D model, cell crosstalk, microenvironment, cancer-associated fibroblast,

#3651 Mesenteric fibrosis in small intestinal neuroendocrine tumors (SI-NETs) – Steps towards understanding its pathogenesis

Introduction: Mesenteric fibrosis (MF) occurs in 50% of patients with SI-NETs, causing significant morbidity and mortality. The pathogenesis of MF in SI-NETs is incompletely understood with no biomarkers or radiological criteria to predict long-term complications of SI-NET associated MF.

Conference:

Presenting Author:

Authors: Hodgetts H, Martins M, Luong T, Hall A, Thirlwell C,

Keywords: small, intestine, neuroendocrine tumor, fibrosis, mesenteric, rna-sequencing, biomarker,

#3486 Treatment response and survival according to molecular alterations in 229 patients with high-grade gastroenteropancreatic neuroendocrine neoplasms (HG GEP-NEN)

Introduction: HG GEP-NEN consist of well-differentiated neuroendocrine tumors (NET G3) and poorly differentiated neuroendocrine carcinoma (NEC). The majority have advanced disease, limited treatment options and a poor prognosis.

Conference:

Presenting Author: Elvebakken H

Authors: Elvebakken H, Venizelos A, Perren A, Couvelard A, Lothe I,

Keywords: neuroendocrine neoplasm, neuroendocrine carcinoma, high-grade, gastroenteropancreatic, molecular alteration, molecular marker,

#2707 Investigating the Crosstalk between MEN1, p53 and Notch Reveals Biomarkers of Formation of Primary Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of endocrine tumors. Previous studies showed that mutations of p53 are extremely rare; whereas genetic changes of MEN1 frequently occur and are correlated with poor prognosis in PNET. Still, their roles in tumorigenesis remain elusive.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Capodanno Y

Authors: Capodanno Y, Chen Y, Hiraoka N, Yokoyama A, Schrader J,

Keywords: MEN1, p53, Notch pathway, biomarkers, carcinogenesis, PNET,